

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Young David (Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106 (Street) HANOVER, MD 21076 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/02/2020	3. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Executive Officer	5. If Amendment, Date Original Filed (Month/Day/Year) 10/02/2020
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Warrants (Right to Buy)	06/29/2018 ⁽¹⁾	06/29/2021	Common Stock	3,147	\$ 19.068	D	
Warrants (Right to Buy)	06/29/2018 ⁽¹⁾	06/29/2021	Common Stock	20,309	\$ 19.068	I	By Family Entities
Warrants (Right to Buy)	06/29/2018 ⁽¹⁾	06/29/2021	Common Stock	15,734	\$ 19.068	I	By Young-Plaisance Revocable Trust
Warrants (Right to Buy)	05/25/2018 ⁽¹⁾	05/25/2021	Common Stock	14,731	\$ 17.164	I	By Young-Plaisance Revocable Trust

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Young David C/O PROCESSA PHARMACEUTICALS, INC. 7300 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076	X		Chief Executive Officer	

Signatures

/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact	10/05/2020
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This amended Form 3 is being filed to add the grant date/exercise date of the warrant issued to the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.